Haleos Labs Limited
Haleos Labs Limited has submitted a regulatory disclosure under SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, specifically referencing Regulation 30(9).
The disclosure serves as an update regarding the US Food and Drug Administration (USFDA) inspection of the company's material subsidiary, Mahi Drugs Private Limited. The inspection was conducted at Mahi Drugs' API manufacturing facility located at Plot No. 82, Jawaharlal Nehru Pharma City, Parawada, Anakapalli - 531019, Andhra Pradesh.
The inspection period was from September 15, 2026, to September 18, 2026. The company reports that the inspection was successfully concluded with zero Form 483 observations. This outcome is consistent with the result of the previous USFDA inspection conducted at the same facility in January 2025, as referenced in the company's earlier communication dated January 24, 2025.
The company states that this successful inspection reflects its continued commitment to maintaining high standards of regulatory compliance, quality, and operational excellence.